Acrux trapped in predator’s crosshairs

Edited by Sarah Thompson

Updated Nov 14, 2009 – 3.05pm, first published at Nov 13, 2009 – 11.05am

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

There are rumours circulating that a potential suitor could lob a bid for emerging biotech company Acrux that would value the stock well north of $3.

The figure is well in excess of what most fund managers would dare hope for with the stock closing at $2.16 on Thursday.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Introducing your Newsfeed

Follow the topics, people and companies that matter to you.

Fetching latest articles